Laboratory Monitoring for Hemochromatosis

Core Monitoring Parameters During Treatment

The American Association for the Study of Liver Diseases recommends monitoring hemoglobin at every phlebotomy session, with a decrease in phlebotomy frequency if hemoglobin falls below 12 g/dL 1
Discontinue phlebotomy entirely if hemoglobin drops below 11 g/dL and reassess with blood tests and clinical evaluation 1
Measure serum ferritin monthly during induction, or after every 4th phlebotomy session, with a target ferritin level of 50-100 μg/L to avoid both under-treatment and iron deficiency 1, 2
Monitor serum ferritin every 6 months during maintenance to ensure levels remain within target range, and adjust phlebotomy schedule based on these results 1

Monitor transaminases (ALT, AST) to assess hepatic involvement, and platelet count to check for thrombocytopenia combined with ferritin >1,000 μg/L, which suggests advanced fibrosis 3, 4
Periodically check plasma folate and plasma cobalamin (vitamin B12), especially in patients requiring numerous phlebotomies, and administer vitamin supplements if deficiencies are detected 1

Unexpected changes in serum ferritin or transferrin saturation should always be investigated, as significant fluctuations are not typical features of hemochromatosis 1
Serum ferritin monitoring is essential to prevent overtreatment and iatrogenic iron deficiency, with depletion to ferritin <50 μg/L leading to further hepcidin reduction and increased iron absorption 1